The self-checkout machine says “unexpected item in bagging area,” and suddenly you are trapped in a philosophical dispute with a scale. Cancer therapy has its own version of this nonsense: a drug can arrive at the tumor cell, recognize the right target, and still fail because the cell basically...
Today’s forecast inside the tumor microenvironment: cloudy with a chance of immune evasion, scattered HER2 signals, and one very suspicious front moving in from the antibody-drug conjugate coast.
Forget that T cells are always brave little cancer-fighting knights. Forget that “boosting the immune system” means flooring the gas pedal and hoping nobody hits a tree. Forget that exhausted T cells are useless couch potatoes in microscopic sweatpants. In this new study, the plot is more...
1999: pathologists finally agree on a name for tiny precancerous pancreatic duct lesions, PanINs. 2021-2025: single-cell and spatial transcriptomics start letting scientists map tumors like suspicious little cities. 2026: Zhuo and colleagues report the rude plot twist: pancreatic cancer may become...
Breaking oncology bulletin: platelets, the tiny emergency sandbags of your bloodstream, may soon receive pharmaceutical backup during chemotherapy. The patients, meanwhile, would like to know whether this backup actually helps them live better, live longer, or simply win a prettier lab report.
The court has seen the evidence, venetoclax looks wildly guilty of helping many AML patients, the verdict has been mostly favorable, and then the appeal arrives: a tiny population of leukemia stem cells claiming, with suspicious confidence, that the whole case was built on the wrong witness.
In Chengdu, China, inside the orbit of West China Hospital and its very serious-looking cancer research machinery, scientists have been inventorying a new class of anti-lung-cancer tools that sound like they escaped from a Cold War spy novel: radionuclide-drug conjugates.
Molecular modifications are the cell’s makeover montage: a tiny chemical accessory here, a protein wardrobe change there, and suddenly biology is walking into the room acting like it has a new stylist. In lung cancer prevention, though, the makeover question is more blunt: after years of cigarette...
At halftime, fibrolamellar liver cancer has been winning partly because the scoreboard had no numbers on it.
Choose your own adventure: A) give chemotherapy alone and hope the tumor gets the memo, or B) add nivolumab, which is basically handing your immune cells a badge, a flashlight, and permission to stop being politely ignored. CheckMate 649 just followed that second path for five years in advanced...
The mystery of cancer coming back after surgery is a little like the mystery of D.B. Cooper: we know something disappeared, we know there were clues, and everyone has a theory that sounds confident until you ask for receipts.
At some point today, you probably turned sugar into energy without sending a single thank-you note to your mitochondria. Rude, honestly. But inside lung tumors, sugar handling is not just housekeeping. It is logistics, construction, security, and occasionally a getaway driver.
What makes a tissue itself: the cells it contains, the job it performs, or the physical mood it keeps under the surface?
What is a tumor, really, if not a group project where one cell did absolutely none of the reading and then took over the room?
Forget that cancer risk is only about the tumor. Forget that mutations are always the main character. Forget that prevention has to mean giving the same drug to a stadium full of people and hoping the math behaves. This new Cell paper asks a sneakier question: what if your blood can reveal when the...
If SEZ6 had an Instagram bio, it might read: "Mostly neuronal, mysteriously overexpressed in small cell lung cancer, available for targeted delivery, no DMs unless attached to chemotherapy."
The weeds are already over the fence, the garden gate is hanging sideways, and somewhere in the brambles a glioblastoma is acting like it owns the whole acre.
The clues were all over the crime scene: a “cold” ovarian tumor with suspiciously few immune cells, a stress protein named GDF15 lurking near the evidence bag, and NK cells - your immune system’s tiny bouncers - suddenly acting like they had been working the door at a nightclub since 1997.
A magician waves one hand at leukemia’s flashy KRAS mutation, asks everyone to watch the sparks, then quietly yanks a tiny fuel pass out of the mitochondria with the other hand. Ta-da: the cancer cell’s powerhouse starts looking less like a power plant and more like a phone at 1% battery during a...
Renovating a cell is normally a terrible idea, like rewiring your kitchen while the toaster is on and the contractor is made of wet spaghetti. But Gao and colleagues just described a microscopic upgrade package: a DNA tetrahedron that slips into a cell, reads three molecular signals, does logic,...